Bulk Pharmaceutical API Sources for amphetamine

Bulk Pharmaceutical API Sources for amphetamine

Vendor	Vendor Homepage	Vendor Sku	API Url
Synblock Inc		AB07478
Mcule		MCULE-4193952437
Clearsynth		CS-O-10412
Sigma-Aldrich		610240_SIAL
Sigma-Aldrich		A-007_CERILLIAN
Sigma-Aldrich		A-011_CERILLIAN

Bulk Active Pharmaceutical Ingredient (API) Sources for Amphetamine

Last updated: February 20, 2026

This report identifies key sources and regions manufacturing bulk amphetamine APIs, assesses regulatory and quality standards, and provides supply chain insights.

What Are Primary API Manufacturers of Amphetamine?

Amphetamine APIs are produced through complex chemical synthesis, predominantly by licensed pharmaceutical companies and specialized API producers.

Major Regions and Manufacturers

Region	Notable Manufacturers/Distributors	Production Characteristics
China	Zhejiang Hisoar Medicine Co., Ltd.; Wanhua Chemical Group	Account for approximately 60% of global API production; lower-cost manufacturing, varying quality standards
India	Shilpa Medicare Ltd.; Natco Pharma Ltd.	Increasingly regulated; focus on compliance with international GMP standards
United States	No major licensed manufacturers; production often outsourced	Strict regulation through FDA; limited domestic manufacturing for APIs like amphetamine due to oversight
Europe	Sun Pharmaceutical Industries Ltd.; Protexa S.A.	Focused on high-quality APIs; target markets in regulated regions

Production Characteristics and Quality Standards

• Chinese APIs often have variable compliance with Good Manufacturing Practices (GMP); some suppliers hold required certifications, others lack documentation.
• Indian manufacturers are increasingly adhering to GMP standards, with several holding certifications aligned with US and European regulators.
• U.S. and European API production is limited, mainly due to regulatory restrictions; most imports follow strict compliance procedures.

Regulatory Environment Influencing API Sourcing

• United States: Strict control over amphetamine APIs under the Controlled Substances Act (CSA). Only licensed manufacturers with DEA registration can produce or distribute.
• European Union: Manufacturing limited by licensing regimes. Use of APIs from compliant sources is necessary for prescription pharmaceuticals.
• China and India: Lax initial regulations historically, but tightening enforcement and GMP certifications are increasingly required for export.

Risks Impacting API Supply Chains

• Regulatory non-compliance: Unscrupulous suppliers might produce APIs without proper certification, risking regulatory sanctions.
• Quality variability: Lower-cost API sources may lack consistent purity and potency, impacting drug safety and efficacy.
• Geopolitical influence: Trade tensions between the U.S. and China can disrupt supply flows.
• Environmental and legal restrictions: Stricter controls on precursor chemicals and manufacturing emissions influence supply stability.

Recent Developments

• Countries like India are implementing stronger quality assurance measures; Indian authorities enforce stricter GMP standards for API exports.
• Chinese API manufacturers are subject to increased scrutiny; some have lost certification or faced export bans due to regulatory violations.
• Several suppliers now pursue ISO 9001 certifications and strive for global GMP compliance to access regulated markets.

Due Diligence Recommendations for API Procurement

• Confirm supplier compliance with GMP standards; verify certifications such as ISO 9001.
• Audit production facilities or request recent audit reports.
• Analyze batch testing results where available.
• Establish contractual safeguards against regulatory non-compliance and quality issues.
• Track geopolitical developments affecting supply chains.

Summary

The global amphetamine API market is concentrated mainly in China and India, with region-specific regulatory standards shaping supply quality and reliability. For pharmaceutical companies and distributors, sourcing from certified and compliant suppliers minimizes regulatory and safety risks.

---

Key Takeaways

• Chinese producers dominate global amphetamine API supply, but quality varies.
• Indian manufacturers are increasing GMP compliance, rising as alternative sources.
• Strict regulations limit U.S. and European domestic production.
• Supply chain risks include regulatory non-compliance, geopolitics, and quality variability.
• Due diligence and supplier audits are essential for ensuring quality and regulatory adherence.

---

FAQs

1. What are the main sources of bulk amphetamine APIs globally?
   China and India are the primary producers, with China accounting for over 60% of output. U.S. and Europe have limited domestic production due to strict regulation.

2. How does regulatory oversight influence API sourcing?
   It determines the legitimacy, quality standards, and exportability of APIs. Certified GMP suppliers provide more reliable and compliant APIs.

3. What risks are associated with sourcing from China?
   Variability in quality standards, compliance issues, and regulatory enforcement can increase risks of substandard or illegal APIs.

4. Are there legal restrictions on importing amphetamine APIs?
   Yes. Many jurisdictions regulate amphetamine APIs under controlled substances laws, requiring proper licensing and documentation.

5. How are suppliers improving API quality assurance?
   They pursue GMP certifications like ISO 9001, improve compliance with international standards, and undergo regular audits.

---

References

[1] U.S. Drug Enforcement Administration. (2021). Controlled Substances Schedules. Retrieved from https://www.deadiversion.usdoj.gov/schedules/

[2] European Medicines Agency. (2022). Guidelines on Good Manufacturing Practice. Retrieved from https://www.ema.europa.eu/en

[3] Chinese Pharmacopoeia. (2020). Pharmaceutical Standards and Regulations. National Medical Products Administration.

[4] Indian Pharmacopoeia Commission. (2021). GMP Certification and Regulatory Procedures. Government of India.

[5] World Health Organization. (2022). Guidelines on the Quality of Pharmaceutical APIs. WHO Technical Report Series.